32618-84-1

Usage

Uses

Used in Pharmaceutical Synthesis:
6-Methoxyquinazoline-2,4-diol is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds, leveraging its unique chemical structure to facilitate the development of new drugs and materials.
Used in Antiviral Applications:
6-Methoxyquinazoline-2,4-diol is used as an antiviral agent, potentially inhibiting viral replication and reducing the severity of viral infections due to its pharmacological properties.
Used in Antitumor Applications:
6-Methoxyquinazoline-2,4-diol is used as an antitumor agent, showing promise in the inhibition of tumor growth and the management of cancer due to its potential biological activities.
Used in Drug Development:
6-Methoxyquinazoline-2,4-diol is used in the development of new drugs, contributing to the advancement of pharmaceutical research and the discovery of novel therapeutic agents with improved efficacy and safety profiles.

Upstream product

• 590-28-3 potassium cyanate 
• 1882-70-8 2-amino-5-methoxybenzoic acid hydrochloride 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 57-13-6 urea 
• 201230-82-2 carbon monoxide 
• 41994-92-7 2-nitro-5-methoxybenzamide 
• 124-38-9 carbon dioxide 
• 23842-82-2 2-amino-5-methoxybenzonitrile 
• 1882-69-5 5-methoxy-2-nitro-benzoic acid 
• 4294-95-5 4-methoxyanthranilic acid 

Downstream Products

• 105763-77-7 2,4-dichloro-6-methoxy-quinazoline 
• 769158-53-4 2-((2-chloro-6-methoxy-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 
• 20197-97-1 2-chloro-6-methoxy-3H-quinazolin-4-one 
• 124309-84-8 2-chloro-6-methoxy-N-methyl-N-phenylquinazolin-4-amine 
• 850424-11-2 2-chloro-6-methoxyquinazoline 
• 952434-87-6 2-chloro-6-methoxy-4-methyl-quinazoline 
• 1036755-97-1 2-chloroquinazolin-6-ol 
• 1313892-51-1 C₂₀H₁₅BrN₄O 

Relevant academic research and scientific papers

Method for preparing 2,4-(1H,3H)-quinazoline diketone compound

The invention discloses a method for preparing a 2,4-(1H,3H)-quinazoline diketone compound. A 2-aminobenzonitrile compound as shown in a formula (1) and carbon dioxide are used as raw materials and react in 2-hydroxypyridine ionic liquid to obtain the 2,4-(1H,3H)-quinazoline diketone compound as shown in a formula (II), and the reaction formula is as shown in the specification. When the ionic liquid is applied to the reaction for preparing the 2,4-(1H,3H)-quinazoline diketone compound, the reaction condition is mild, the separation and purification process of the product is simple, the product yield is high, and the substrate application range is wide.

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Facile and efficient synthesis of quinazoline-2,4(1H,3H)-diones through sequential hydrogenation condensation

The heterocyclizations from various methyl (2-nitrobenzoyl)carbamates to substituted quinazoline-2,4(1H,3H)-diones under hydrogenation conditions were investigated in this study. In the presence of p-toluenesulfonic acid monohydrate in methanol, various q

HISTONE DEACETYLASE AND HISTONE METHYLTRANSFERASE INHIBITORS AND METHODS OF MAKING AND USE OF THE SAME

The compounds of formula (I) are dual inhibitors of the enzymes histone deacetylases (HDACs) and histone methyltransferase G9a, both of which are key posttranslational enzymes in cancer development.

SUBSTITUTED QUINAZOLINE COMPOUNDS AND PREPARATION AND USES THEREOF

The present invention relates quinazolinone compounds of Formula (I), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses； wherein the compounds or pharmaceutical compositions disclosed herein can be used for antagonizing the orexin receptor. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing neurological and psychiatric disorders and diseases of the central nervous system in mammals, especially in humans.

OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF

The invention relates to octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof. Compounds and pharmaceutical compositions comprising the compounds provided herein are used for antagonizing orexin receptors. The invention also relates to processes for preparing the compounds and pharmaceutical compositions, and uses thereof in treating or preventing a disease related to orexin receptors.

The therapeutic compound, use and related method (by machine translation)

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition containing a compound or its salt which prevents or treats a central nervous system disease in which integration dysfunction syndrome and agnosia are enumerated as exemplary disorders.SOLUTION: The pharmaceutical composition includes the compound or its salt represented by chemical formula (A) which modulates striatal-enriched protein tyrosine phosphatase (STEP).

BICYCLIC DERIVATIVE CONTAINING PYRIMIDINE RING, AND PREPARATION METHOD THEREFOR

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.

Octahydropyrrole[3, 4-c]pyrrole derivative and using method and application thereof

The invention relates to an ctahydropyrrole[3, 4-c]pyrrole derivative and a using method and application thereof. A compound and a drug composition containing the same are used for resisting orexin receptors. The invention further relates to methods of pr

Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists

Protease-activated receptor 2 (PAR2) is a member of G protein-coupled receptor and its activation initiates diverse inflammatory responses. Recent studies suggest that antagonists of PAR2 may provide a novel therapeutic strategy for inflammatory diseases. In this study, we have developed a series of 2-aryloxy-4-amino-quinazoline derivatives as PAR2 antagonists and examined their effects against LPS-induced inflammatory responses in RAW 264.7 macrophages. Among these derivatives, compound 2f displayed the greatest antagonistic activity with the IC50 value of 2.8 μM. Binding modes of the newly identified PAR2 antagonists were analyzed by molecular docking using IFD/MM-GBSA methods in the putative binding site of PAR2 homology model. Moreover, 2f demonstrated significant inhibitory effects on the LPS-activated pro-inflammatory mediators including nitric oxide (NO), prostaglandin E2 (PGE2), interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) through the regulation of various intracellular signaling pathways involving nuclear factor-κB (NF-κB), activator protein 1 (AP-1) and the mitogen-activated protein kinases (MAPK). Furthermore, administration of 2f significantly reduced the mortality of LPS-induced sepsis in mice. These results provide useful insights into the development of novel PAR2 antagonists with anti-inflammatory activity in vitro and in vivo.